Finch Therapeutics appoints Marc Blaustein as COO effective Sept 8

Finch Therapeutics Group, Inc.

Marc Blaustein appointed COO, effective September 8, 2021.
Base salary of $400,000; target bonus of 40% of base salary; options for 150,000 shares vesting over 4 years.
Blaustein brings 20+ years biopharma experience, including roles at Dyax, Alkermes, and as CEO of NED Biosystems.
CEO Mark Smith says Blaustein's operational expertise will be valuable as Finch enters next phase of growth.
Severance includes 9 months salary (non-CIC) or 12 months salary (CIC) plus equity acceleration.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Marc Blaustein

Chief Operating Officer

FNCHQ · Finch Therapeutics Group, Inc.

Effective: 2021-09-08
Filed: September 8, 2021, 7:59 PM ET

appointed Marc Blaustein to serve as the Company’s Chief Operating Officer, effective September 8, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Marc Blaustein was appointed as Chief Operating Officer at Finch Therapeutics Group, Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

appointed Marc Blaustein to serve as the Company’s Chief Operating Officer, effective September 8, 2021.

View on SEC.gov

Finch Therapeutics Group, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-21-047253

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.